| Robert L Mazor, | |
|
4800 Sand Point Way Ne, Seattle, WA 98105-3901 | |
| (206) 987-2000 | |
| Not Available |
| Full Name | Robert L Mazor |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Critical Care Medicine |
| Location | 4800 Sand Point Way Ne, Seattle, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023108917 | NPI | - | NPPES |
| 322830 | Other | INTERNAL ID-MOTOR VEHICLE ID | |
| 8398497 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0203X | Pediatrics - Pediatric Critical Care Medicine | MD00043820 (Washington) | Primary |
| Entity Name | The Association Of Chrmc And University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255449963 PECOS PAC ID: 9133032964 Enrollment ID: O20031107000585 |
News Archive
A device designed by a team of faculty and student researchers at Sheridan's Centre for Mobile Innovation (CMI) has the potential to impact the diagnosis of community-acquired pneumonia - a significant cause of death for children worldwide, according to the World Health Organization.
Children who were exposed to higher levels of trace minerals manganese and selenium during their mothers' pregnancy had a lower risk of high blood pressure in childhood, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Researchers studying how the brain makes decisions have, for the first time, recorded the moment-by-moment fluctuations in brain signals that occur when a monkey making free choices has a change of mind.
A smokeless cannabis-vaporizing device delivers the same level of active therapeutic chemical and produces the same biological effect as smoking cannabis, but without the harmful toxins, according to UCSF researchers.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert L Mazor, 4500 Sand Point Way Ne, #100, Seattle, WA 98105-3900 Ph: () - | Robert L Mazor, 4800 Sand Point Way Ne, Seattle, WA 98105-3901 Ph: (206) 987-2000 |
News Archive
A device designed by a team of faculty and student researchers at Sheridan's Centre for Mobile Innovation (CMI) has the potential to impact the diagnosis of community-acquired pneumonia - a significant cause of death for children worldwide, according to the World Health Organization.
Children who were exposed to higher levels of trace minerals manganese and selenium during their mothers' pregnancy had a lower risk of high blood pressure in childhood, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Researchers studying how the brain makes decisions have, for the first time, recorded the moment-by-moment fluctuations in brain signals that occur when a monkey making free choices has a change of mind.
A smokeless cannabis-vaporizing device delivers the same level of active therapeutic chemical and produces the same biological effect as smoking cannabis, but without the harmful toxins, according to UCSF researchers.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
› Verified 4 days ago
Dr. James Toliver Bennett Jr., M.D., PH.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 4800 Sand Point Way Ne, Genetic Medicine, Seattle, WA 98105 Phone: 206-987-2056 | |
Dr. Leslie Ann Dervan, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4800 Sand Point Way Ne, Mb.10.620, Seattle, WA 98105 Phone: 206-987-0293 | |
Dr. Indi Trehan, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 4800 Sand Point Way Ne, Seattle, WA 98105 Phone: 206-987-2000 | |
Alexa Mason, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4800 Sand Point Way Ne # Oc.7830, Seattle, WA 98105 Phone: 206-987-2525 | |
Dr. Gloria A. Arand, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 125 16th Ave E, Seattle, WA 98112 Phone: 206-326-3530 | |
Marcella Theresia Mascher Denen, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1959 Ne Pacific St, C212, Box 356340, Seattle, WA 98195 Phone: 206-543-0065 | |
Elizabeth Amy Hicks, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 4800 Sand Point Way Ne, Seattle, WA 98105 Phone: 206-987-2599 Fax: 206-987-2599 |